Merlin

Also added to the label is a statement that cites the significantly lower rate of arrhythmias in patients with coronary heart disease who were treated with ranolazine in the MERLIN-TIMI 36 trial, compared with those on placebo, CV Therapeutics Inc.

In a statement, the company said that data from the MERLIN-TIMI 36 trial were submitted to the FDA in September 2007, as part of its supplemental application.

The MERLIN-TIMI 36 trial (Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes), a large-scale trial of 4513 patients with ACS, demonstrated a 3-fold higher adjusted risk of death and recurrent MI at 30 days and a 2.

Morrow noted in presenting the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndrome-Thrombolysis in Ml) results at the annual meeting of the American College of Cardiology.

Morrow noted in presenting the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndrome--Thrombolysis in MI) results at the annual meeting of the American College of Cardiology.